Literature DB >> 1985698

Molecular defect in coagulation factor XFriuli results from a substitution of serine for proline at position 343.

H L James1, A Girolami, D S Fair.   

Abstract

Our previous findings suggested that coagulation factor XFriuli could be functionally defective owing to a point mutation in the portion of the factor X gene coding for the fully activated heavy chain. To verify the existence of this postulated change, we analyzed all eight exons of the normal and Friuli factor X gene. Each exon was amplified from genomic DNA using the polymerase chain reaction and cloned into the plasmid pUC19. The amplified DNA inserts were subjected to direct sequencing by the dideoxy chain termination method with forward and reverse oligonucleotide sequencing primers. A point mutation (C to T transition at nucleotide position 19,297) that results in coding for serine (TCC) in place of proline (CCC) at amino acid position 343 was found. This substitution involves a highly conserved proline residue oriented spatially close to both the cleavage site of the zymogen and the active site of the enzyme and explains the previous observations of discrete biochemical and functional differences between factor XFriuli and normal factor X. The mutation abolished an HgiCI restriction site present in the normal factor X gene, and this change constitutes the basis for a convenient method for screening individuals carrying this molecular defect. Proline343 is in conserved region 5 of the serine protease superfamily to which factor X belongs and is part of a 14-residue L*****P******C motif that occurs in at least 16 other enzymes. Computer analysis suggests that the motif may be an essential aspect of conformational features important to functional properties of factor X as well as other serine proteases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985698

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7).

Authors:  G Marchetti; P Patracchini; D Gemmati; V DeRosa; M Pinotti; G Rodorigo; A Casonato; A Girolami; F Bernardi
Journal:  Hum Genet       Date:  1992-07       Impact factor: 4.132

2.  A Phenome-Wide Association Study Uncovers a Pathological Role of Coagulation Factor X during Acinetobacter baumannii Infection.

Authors:  Jacob E Choby; Andrew J Monteith; Lauren E Himmel; Paris Margaritis; Jana K Shirey-Rice; Andrea Pruijssers; Rebecca N Jerome; Jill Pulley; Eric P Skaar
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

3.  Factor XSanto Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion.

Authors:  H H Watzke; A Wallmark; N Hamaguchi; P Giardina; D W Stafford; K A High
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

4.  Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.

Authors:  Majed N Aljamali; Paris Margaritis; Alexander Schlachterman; Shing Jen Tai; Elise Roy; Ralph Bunte; Rodney M Camire; Katherine A High
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

5.  Factor XKetchikan: a variant molecule in which Gly replaces a Gla residue at position 14 in the light chain.

Authors:  D J Kim; A R Thompson; H L James
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

6.  A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X.

Authors:  S J Tai; R W Herzog; P Margaritis; V R Arruda; K Chu; J A Golden; P A Labosky; K A High
Journal:  J Thromb Haemost       Date:  2007-11-23       Impact factor: 5.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.